ArticleCommunications medicine2025
Artificial intelligence-derived photoplethysmography age as a digital biomarker for cardiovascular health.
Article in Communications medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Predicting the Risk of Cardiovascular Diseases in the Elderly Based on Clinical Data and Heart Rate Variability Using Machine Learning.Journal of clinical medicine · 2026Article
- Artificial intelligence as a computational kit for digital biomarker discovery.Journal of translational internal medicine · 2026Article
- Vascular Age: A narrative review of assessment methods, clinical applications, and future directions.International journal of cardiology. Cardiovascular risk and prevention · 2026Review
- Data-hugging shields proprietary AI models from research that could disprove them.NPJ artificial intelligence · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundPhotoplethysmography (PPG), increasingly available through wearable devices, provides a non-invasive means of monitoring human hemodynamics. In this study, we introduce artificial intelligence-derived photoplethysmography (AI-PPG) age, a deep learning-based estimate of biological age from raw PPG signals, and evaluate its potential as a digital biomarker for cardiovascular health.
methodsWe developed a deep learning model with a distribution-aware loss function to reduce bias from imbalanced data. The model was trained and evaluated on the UK Biobank cohort (N = 212,231). We analyzed the association between the AI-PPG age gap (AI-PPG age minus calendar age) and multiple cardiovascular and metabolic outcomes, assessed its longitudinal value using serial PPG measurements, and externally validated its generalizability in an independent MIMIC-III-derived cohort (N = 2343).
resultsAfter adjusting for key confounders, participants with an AI-PPG age gap greater than 9 years have a significantly higher risk of major adverse cardiovascular and cerebrovascular events (hazard ratio of 2.37, p = 8.46 × 10
conclusionsAI-PPG age is a scalable, non-invasive biomarker for cardiovascular health assessment. Integrated with wearable devices, it may enable population-level screening, personalized monitoring, and early intervention.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.